![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
AC Howlett, MR Johnson, LS Melvin and GM Milne
Department of Pharmacology, St. Louis University Medical School, Missouri 63104.
Extensive structure-activity relationship studies have demonstrated that specific requirements within the cannabinoid structure are necessary to produce potent analgesia. A three-point association between the agonist and the receptor mediating analgesia consists of: 1) the C ring hydroxyl, 2) the phenolic A ring hydroxyl, and 3) the A ring alkyl hydrophobic side chain. Potent tricyclic and bicyclic structures were synthesized as "nonclassical" cannabinoid analgetics that conform to this agonist-receptor three-point interaction model. At the cellular level, centrally active cannabinoid drugs inhibit adenylate cyclase activity in a neuroblastoma cell line. The structure- activity relationship profile for inhibition of adenylate cyclase in vitro was consistent with this same three-point association of agonists with the receptor. A correlation exists between the potency of drugs to produce analgesia in vivo and to inhibit adenylate cyclase in vitro. Enantio- and stereoselectivity were exhibited by the nonclassical cannabinoid compounds for both the analgetic response and the ability to inhibit adenylate cyclase. The magnitude of the enantioselective response was equal for both the biochemical and physiological endpoints. Based on the parallels in structure-activity relationships and the enantioselective effects, it is postulated that the receptor that is associated with the regulation of adenylate cyclase in vitro may be the same receptor as that mediating analgesia in vivo. A conceptualization of the cannabinoid analgetic receptor is presented.
This article has been cited by other articles:
|
|
 |
|
  C. Liu and J. M. Walker Effects of a Cannabinoid Agonist on Spinal Nociceptive Neurons in a Rodent Model of Neuropathic Pain J Neurophysiol, December 1, 2006; 96(6): 2984 - 2994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yoshihara, H. Morimoto, Y. Yamada, T. Abe, and O. Arisaka Cannabinoid Receptor Agonists Inhibit Sensory Nerve Activation in Guinea Pig Airways Am. J. Respir. Crit. Care Med., November 1, 2004; 170(9): 941 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Klein, C. Newton, K. Larsen, L. Lu, I. Perkins, L. Nong, and H. Friedman The cannabinoid system and immune modulation J. Leukoc. Biol., October 1, 2003; 74(4): 486 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Iversen Cannabis and the brain Brain, June 1, 2003; 126(6): 1252 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Sim-Selley and B. R. Martin Effect of Chronic Administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Delta 9-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 36 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Klein, B. Lane, C. A. Newton, and H. Friedman The Cannabinoid System and Cytokine Network Experimental Biology and Medicine, October 1, 2000; 225(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
B. R. Martin, R. Jefferson, R. Winckler, J. L. Wiley, J. W. Huffman, P. J. Crocker, B. Saha, and R. K. Razdan Manipulation of the Tetrahydrocannabinol Side Chain Delineates Agonists, Partial Agonists, and Antagonists J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1065 - 1079. [Abstract] [Full Text]
|
|
|
|
|
|
N. M. Strangman and J. M. Walker Cannabinoid WIN 55,212-2 Inhibits the Activity-Dependent Facilitation of Spinal Nociceptive Responses J Neurophysiol, July 1, 1999; 82(1): 472 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Carayon, J. Marchand, D. Dussossoy, J.-M. Derocq, O. Jbilo, A. Bord, M. Bouaboula, S. Galiegue, P. Mondiere, G. Penarier, et al. Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation Blood, November 15, 1998; 92(10): 3605 - 3615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Aceto, S. M. Scates, R. K. Razdan, and B. R. Martin Anandamide, an Endogenous Cannabinoid, Has a Very Low Physical Dependence Potential J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 598 - 605. [Abstract] [Full Text]
|
|
|
|
|
|
W. Zhu, H. Friedman, and T. W. Klein Delta 9-Tetrahydrocannabinol Induces Apoptosis in Macrophages and Lymphocytes: Involvement of Bcl-2 and Caspase-1 J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1103 - 1109. [Abstract] [Full Text]
|
|
|
|
|
|
B. F. Thomas, A. F. Gilliam, D. F. Burch, M. J. Roche, and H. H. Seltzman Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 285 - 292. [Abstract] [Full Text]
|
|
|
|
|
|
C. C. Felder, K. E. Joyce, E. M. Briley, M. Glass, K. P. Mackie, K. J. Fahey, G. J. Cullinan, D. C. Hunden, D. W. Johnson, M. O. Chaney, et al. LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 291 - 297. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Shen, T. M. Piser, V. S. Seybold, and S. A. Thayer Cannabinoid Receptor Agonists Inhibit Glutamatergic Synaptic Transmission in Rat Hippocampal Cultures J. Neurosci., July 15, 1996; 16(14): 4322 - 4334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Condie, A. Herring, W. S. Koh, M. Lee, and N. E. Kaminski Cannabinoid Inhibition of Adenylate Cyclase-mediated Signal Transduction and Interleukin 2 (IL-2) Expression in the Murine T-cell Line, EL4.IL-2 J. Biol. Chem., May 31, 1996; 271(22): 13175 - 13183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Xie, L. S. Melvin, and A. Makriyannis The Conformational Properties of the Highly Selective Cannabinoid Receptor Ligand CP-55,940 J. Biol. Chem., May 3, 1996; 271(18): 10640 - 10647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bayewitch, M.-H. Rhee, T. Avidor-Reiss, A. Breuer, R. Mechoulam, and Z. Vogel (-)-Delta^9-Tetrahydrocannabinol Antagonizes the Peripheral Cannabinoid Receptor-mediated Inhibition of Adenylyl Cyclase J. Biol. Chem., April 26, 1996; 271(17): 9902 - 9905. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
